Duvelisib was the second PI3K inhibitor authorized from the FDA, also based on a stage III randomized demo.one hundred thirty The efficacy and protection profile of the drug show up equivalent with These of idelalisib, Otherwise marginally advantageous. Regarding substitute BTK inhibitors, there are numerous products in progress, but only acalabrut